150 related articles for article (PubMed ID: 32301258)
1. Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab.
Jordan SC; Kucher K; Bagger M; Hockey HU; Wagner K; Ammerman N; Vo A
Am J Transplant; 2020 Sep; 20(9):2581-2588. PubMed ID: 32301258
[TBL] [Abstract][Full Text] [Related]
2. Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency.
Salerno SN; Deng R; Kakkar T
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1316-1327. PubMed ID: 35860862
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.
Redfield RR; Jordan SC; Busque S; Vincenti F; Woodle ES; Desai N; Reed EF; Tremblay S; Zachary AA; Vo AA; Formica R; Schindler T; Tran H; Looney C; Jamois C; Green C; Morimoto A; Rajwanshi R; Schroeder A; Cascino MD; Brunetta P; Borie D
Am J Transplant; 2019 Nov; 19(11):3035-3045. PubMed ID: 31257724
[TBL] [Abstract][Full Text] [Related]
4. Severe antibody-mediated rejection following IVIG infusion in a kidney transplant recipient with BK-virus nephropathy.
Mainra R; Xu Q; Chibbar R; Hassan A; Shoker A
Transpl Immunol; 2013 Jun; 28(4):145-7. PubMed ID: 23685054
[TBL] [Abstract][Full Text] [Related]
5. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
6. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients.
Jordan SC; Toyoda M; Kahwaji J; Vo AA
Am J Transplant; 2011 Feb; 11(2):196-202. PubMed ID: 21219579
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
[TBL] [Abstract][Full Text] [Related]
8. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
[TBL] [Abstract][Full Text] [Related]
9. Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation.
Jeong JC; Jambaldorj E; Kwon HY; Kim MG; Im HJ; Jeon HJ; In JW; Han M; Koo TY; Chung J; Song EY; Ahn C; Yang J
Medicine (Baltimore); 2016 Feb; 95(5):e2635. PubMed ID: 26844479
[TBL] [Abstract][Full Text] [Related]
10. Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy.
Pinelli DF; Zachary AA; Friedewald JJ; Gjertson DW; Evans MA; Chatroop EN; Leffell MS; Vo AA; Jordan SC; Montgomery RA; Tambur AR
Am J Transplant; 2019 Feb; 19(2):381-390. PubMed ID: 29981209
[TBL] [Abstract][Full Text] [Related]
11. Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.
Zhu D; Ravindranath MH; Terasaki PI; Miyazaki T; Pham T; Jucaud V
Clin Exp Immunol; 2014 Aug; 177(2):464-77. PubMed ID: 24611451
[TBL] [Abstract][Full Text] [Related]
12. Anti-Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation.
Staley EM; Carruba SS; Manning M; Pham HP; Williams LA; Marques MB; Locke JE; Lorenz RG
Am J Transplant; 2016 Aug; 16(8):2483-6. PubMed ID: 26913485
[TBL] [Abstract][Full Text] [Related]
13. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
14. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.
Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA
Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910
[TBL] [Abstract][Full Text] [Related]
15. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
16. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.
Vo AA; Choi J; Cisneros K; Reinsmoen N; Haas M; Ge S; Toyoda M; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2014 Aug; 98(3):312-9. PubMed ID: 24770617
[TBL] [Abstract][Full Text] [Related]
17. Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.
Orandi BJ; Lonze BE; Jackson A; Terezakis S; Kraus ES; Alachkar N; Bagnasco SM; Segev DL; Orens JB; Montgomery RA
Am J Transplant; 2016 Oct; 16(10):3041-3045. PubMed ID: 27214874
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin induction therapy in renal transplant recipients: Effects on immunoglobulin and regulatory antibody levels.
Staak A; Renner F; Suesal C; Dietrich H; Rainer L; Kamali-Ernst S; Ernst W; Padberg W; Opelz G; Weimer R
Transplant Proc; 2006 Dec; 38(10):3483-5. PubMed ID: 17175311
[TBL] [Abstract][Full Text] [Related]
20. Successful desensitization and kidney transplantation in the presence of donor-specific anti-human leukocyte antigen antibodies in kidney transplant recipients.
Khan MT; Hamid RB; Sarfaraz S; Lal N; Ahmed J; Luxmi S
Saudi J Kidney Dis Transpl; 2020; 31(6):1432-1438. PubMed ID: 33565460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
